Birgitte Volck

Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration

TFS Trial Form Support AB provides clinical trial services. The firm operates as a clinical contract research organization. Its services include regulatory affairs, feasibility, global clinical operations, study and site coordination, patient recruitment services, clinical data management, edc systems, biostatistics, pharmacovigilance/safety, medical writing, quality assurance, tfs academy, and functional service solutions. The company was founded by Daniel Spasic in 1996 and is headquartered in Lund, Sweden.